2024-09-19FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutationsTrial MARIPOSA-2Drugs Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody, carboplatin · Platinum agent, pemetrexed · AntifolateConditionThoracic
2024-09-17FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesotheliomaDrugs Keytruda (pembrolizumab) · Anti-PD-1 antibody, pemetrexed · AntifolateConditionsOther solid neoplasmThoracic
2024-03-01FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indicationsTrial PAPILLONDrugs Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody, carboplatin · Platinum agent, pemetrexed · AntifolateConditionThoracic
2018-08-20FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLCTrial MK-3475-189Drugs KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, pemetrexed · AntifolateConditionThoracic